This HTML5 document contains 120 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00493/identifier/chebi/
n23http://linked.opendata.cz/resource/AHFS/
n19http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n16http://linked.opendata.cz/resource/drugbank/mixture/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00493/identifier/wikipedia/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00493/identifier/pharmgkb/
n14http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00493/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n15http://www.rxlist.com/cgi/generic/
n24http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00493/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n25http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n10http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00493/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00493
rdf:type
n3:Drug
n3:description
Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).
n3:dosage
n22:271B5E1D-363D-11E5-9242-09173F13E4C5 n22:271B5E1E-363D-11E5-9242-09173F13E4C5 n22:271B5E1F-363D-11E5-9242-09173F13E4C5 n22:271B5E20-363D-11E5-9242-09173F13E4C5 n22:271B5E21-363D-11E5-9242-09173F13E4C5 n22:271B5E22-363D-11E5-9242-09173F13E4C5 n22:271B5E23-363D-11E5-9242-09173F13E4C5 n22:271B5E24-363D-11E5-9242-09173F13E4C5 n22:271B5E25-363D-11E5-9242-09173F13E4C5 n22:271B5E18-363D-11E5-9242-09173F13E4C5 n22:271B5E19-363D-11E5-9242-09173F13E4C5 n22:271B5E1A-363D-11E5-9242-09173F13E4C5 n22:271B5E1B-363D-11E5-9242-09173F13E4C5 n22:271B5E1C-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
Approximately 1 hour.
n3:indication
Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.
n3:manufacturer
n19:271B5E04-363D-11E5-9242-09173F13E4C5 n19:271B5E05-363D-11E5-9242-09173F13E4C5 n19:271B5E0C-363D-11E5-9242-09173F13E4C5 n19:271B5E0A-363D-11E5-9242-09173F13E4C5 n19:271B5E0B-363D-11E5-9242-09173F13E4C5 n19:271B5E08-363D-11E5-9242-09173F13E4C5 n19:271B5E09-363D-11E5-9242-09173F13E4C5 n19:271B5E06-363D-11E5-9242-09173F13E4C5 n19:271B5E07-363D-11E5-9242-09173F13E4C5
owl:sameAs
n14:DB00493 n24:DB00493
dcterms:title
Cefotaxime
adms:identifier
n6:204928 n7:DB00493 n8:PA448852 n11:64679-947-01 n12:C06885 n27:Cefotaxime
n3:mechanismOfAction
The bactericidal activity of cefotaxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefotaxime shows high affinity for penicillin-binding proteins in the cell wall including PBP Ib and PBP III.
n3:packager
n19:271B5E00-363D-11E5-9242-09173F13E4C5 n19:271B5E01-363D-11E5-9242-09173F13E4C5 n19:271B5DFE-363D-11E5-9242-09173F13E4C5 n19:271B5DFF-363D-11E5-9242-09173F13E4C5 n19:271B5E02-363D-11E5-9242-09173F13E4C5 n19:271B5E03-363D-11E5-9242-09173F13E4C5 n19:271B5DF8-363D-11E5-9242-09173F13E4C5 n19:271B5DF9-363D-11E5-9242-09173F13E4C5 n19:271B5DF7-363D-11E5-9242-09173F13E4C5 n19:271B5DFC-363D-11E5-9242-09173F13E4C5 n19:271B5DFD-363D-11E5-9242-09173F13E4C5 n19:271B5DFA-363D-11E5-9242-09173F13E4C5 n19:271B5DFB-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Approximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite.
n3:synonym
Cefotaxima (6R,7R,Z)-3-(Acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid Cefotaximum (6R,7R)-3-(Acetoxymethyl)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (6R,7R)-3-Acetoxymethyl-7-{2-(2-amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid CĂ©fotaxime Cefotaxim Cephotaxime
n3:toxicity
Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions. Oral rat LD<sub>50</sub> is over 20,000 mg/kg while intravenous rat LD<sub>50</sub> is over 7,000 mg/kg.
n20:hasAHFSCode
n23:08-12-06-12
n3:mixture
n16:271B5DF6-363D-11E5-9242-09173F13E4C5 n16:271B5DF4-363D-11E5-9242-09173F13E4C5 n16:271B5DF5-363D-11E5-9242-09173F13E4C5 n16:271B5DF3-363D-11E5-9242-09173F13E4C5
n3:salt
n3:synthesisReference
Ingolf Macher, Gerhard Widschwenter, "Production of cefotaxime and new sodium salts." U.S. Patent US5831086, issued May, 1992.
n25:hasConcept
n26:M0003722
foaf:page
n10:cefotaxime.html n15:cefotax.htm
n3:IUPAC-Name
n4:271B5E2A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5E30-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5E2F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5E2C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5E2D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5E2E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5E40-363D-11E5-9242-09173F13E4C5 n4:271B5E28-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5E41-363D-11E5-9242-09173F13E4C5 n4:271B5E26-363D-11E5-9242-09173F13E4C5 n4:271B5E29-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5E27-363D-11E5-9242-09173F13E4C5
n20:hasATCCode
n21:J01DD01
n3:H-Bond-Acceptor-Count
n4:271B5E36-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5E37-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5E31-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5E32-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5E34-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5E33-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5E35-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed following intramuscular injection.
n3:affectedOrganism
Neisseria gonorrhoeae Salmonella typhi Neisseria meningitidis Haemophilus influenzae Enteric bacteria and other eubacteria Escherichia coli
n3:casRegistryNumber
63527-52-6
n3:category
n3:containedIn
n18:271B5E13-363D-11E5-9242-09173F13E4C5 n18:271B5E14-363D-11E5-9242-09173F13E4C5 n18:271B5E11-363D-11E5-9242-09173F13E4C5 n18:271B5E12-363D-11E5-9242-09173F13E4C5 n18:271B5E17-363D-11E5-9242-09173F13E4C5 n18:271B5E15-363D-11E5-9242-09173F13E4C5 n18:271B5E16-363D-11E5-9242-09173F13E4C5 n18:271B5E0D-363D-11E5-9242-09173F13E4C5 n18:271B5E0F-363D-11E5-9242-09173F13E4C5 n18:271B5E10-363D-11E5-9242-09173F13E4C5 n18:271B5E0E-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5E3C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5E3E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5E3F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5E3B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5E3A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5E3D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5E2B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5E38-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5E39-363D-11E5-9242-09173F13E4C5